SwissHealth Ventures: digital, innovative, personal.

Who we are

SwissHealth Ventures AG is a member of the CSS Group, Switzerland's leading health insurer. We are the ideal healthcare partner for ambitious start-ups in the field of digital health.

Our industry-specific expertise is com­plemented by the support of experienced venture capital partner Redstone, enabling agile and sustainable growth.

Our investment focus

We invest in start-ups that advance healthcare with new digital technologies and strive for synergies with the CSS Group. With targeted investments, we want to support people in staying healthy, getting healthy, or living with an illness. In addition, we focus on digital solutions that directly increase efficiency for the core business of health insurers.

Get Funded

Does your start-up fit our investment criteria and are there potential synergies with the CSS Group? Then we look forward to hearing from you.

Portfolio

Heartbeat Medical operates a platform that links patient-reported outcomes (PROs) with clinical data to evaluate treatment. PROs use standardised questionnaires to measure how patients assess the outcome of their treatment and their health-related quality of life. Linking them with clinical data provides a sound basis for data-driven decision-making on medical, therapeutic and economic matters. In this way, for instance, Heartbeat Medical facilitates quality-centred reimbursement models. In addition to active use of the platform by hospitals, PROs have recently been gaining more attention in the context of cantonal quality assurance.

Data-driven treatment paths not only mean measurable outcomes and a better quality of life for patients: the improved quality of care can also help to curb healthcare costs.

Humanoo has developed a platform for digital health management that helps make people and organisations healthier. The digital health company offers numerous on-demand programmes for fitness, physio, yoga, mindfulness, sleep and nutrition. SwissHealth Ventures invested in this start-up in 2021 as lead investor in the series B round (which raised a total of USD 10 million in funding from all investors). The capital raised gives Humanoo the resources required to further develop its core product and keep growing.

Humanoo also forms the basis for the CSS active365 (in German) rewards app. Users get access to Humanoo programmes and are rewarded with up to CHF 600 a year for leading a healthy lifestyle.

The Flow Neuroscience start-up offers a digital and medication-free therapy for treating clinical depression. The combi­nation therapy consists of a brain stimu­lation headset coupled with a behavioral therapy app. This enables patients to treat depression under guidance at home or in the company of a specialist. SwissHealth Ventures invested in this start-up in 2021 as co-lead investor in the series A round, along with Khosla Ventures and Zühlke Ventures. The additional capital raised will enable Flow Neuroscience to tailor the existing solution more specifically to the individual patient, expand on its offering designed for use in interventions supervised by a professional, and access new markets.

The Flow Neuroscience solution aims to personalise the treatment of people with mental health problems. SwissHealth Ventures is convinced that this innovative form of therapy will close a gap in the healthcare market.

With OnlineDoctor, skin problems can be assessed quickly, regardless of location and at low cost by dermatologists licensed in Switzerland. Via a web-based platform, patients receive an initial specialist assessment including a recommendation for action within 48 hours. SwissHealth Ventures participated in 2020 as lead investor in this Swiss telemedicine start-up as part of the A-round (investment volume of all investors total around 5.5 million Swiss francs).

CSS has already made this service a fixed part of its offering, where it is known as the «online skin check». The uncompli­cated skin check by Swiss dermatologists contributes to digital integrated care.

Pregnolia has developed a device that supports the diagnosis of premature birth. It enables gynaecologists to measure cervical stiffness more precisely and thus make a better assessment of the risk of premature birth. SwissHealth Ventures invested in this ETH spin-off in 2020 in the series A round (which raised a total of 4.2 million Swiss francs in funding from all investors).

SwissHealth Ventures believes in the success of the Pregnolia measurement system and its ability to provide great reassurance to professionals and pregnant women. In addition, we believe that this method will reduce healthcare costs in the long term.